GORE VIABAHN VBX Balloon Expandable Endoprosthesis
W. L. Gore & Associates, Inc. · Decision date Oct 17, 2025
What did the FDA decide?
FDA records P160021/S049 as a supplement to PMA P160021, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 17, 2025.
FDA approval order statement
implementation of an additional supplier of a raw material of the CBAS Heparin Surface
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 17, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P160021/S049
- Regulatory pathway
- PMA supplement
- Applicant
- W. L. Gore & Associates, Inc.
- Product code
- PRL
- Decision code
- OK30
- Decision date
- Oct 17, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Iliac covered stent, arterial.
- Applicant
- W. L. Gore & Associates, Inc.
- Product code
- PRL
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P160021. Subsequent supplements may change the device or its indications.
FDA decision timeline
P160021 · Original PMA
GORE VIABAHN VBX BALLOON EXPANDABLE ENDOPROSTHESIS
P160021/S049 received
Application receipt date recorded by FDA.
P160021/S049 · FDA decision
30-Day Notice
P160021/S048 · Related supplement
GORE VIABAHN VBX Balloon Expandable Endoprosthesis
P160021/S050 · Related supplement
GORE VIABAHN VBX Balloon Expandable Endoprosthesis
P160021/S052 · Related supplement
GORE VIABAHN VBX Balloon Expandable Endoprosthesis
P160021/S051 · Related supplement
GORE VIABAHN VBX Balloon Expandable Endoprosthesis
Timeline entries are records held by MedtechLedger for P160021. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160021
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| W. L. Gore & Associates, Inc. | PMA approval | Jan 27, 2017 | FDA | |
| W. L. Gore & Associates, Inc. | PMA supplement | Nov 24, 2025 | FDA | |
| W. L. Gore & Associates, Inc. | PMA supplement | Feb 5, 2026 | FDA | |
| W. L. Gore & Associates, Inc. | PMA supplement | Jun 16, 2026 | FDA | |
| W. L. Gore & Associates, Inc. | PMA supplement | Oct 8, 2026 | FDA |
Explore the linked device profile
Other records with product code PRL
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
iCast Covered Stent SystemP120003/S007 | Atrium Medical Corp. | PMA supplement | May 13, 2026 | FDA |
iCast Covered Stent SystemP120003/S009 | Atrium Medical Corp. | PMA supplement | Dec 22, 2025 | FDA |
| Bard Peripheral Vascular, Inc. | PMA supplement | Sep 29, 2025 | FDA | |
iCast Covered Stent SystemP120003/S011 | Atrium Medical Corp. | PMA supplement | Sep 12, 2025 | FDA |
iCast Covered Stent SystemP120003/S010 | Atrium Medical Corp. | PMA supplement | Aug 20, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
W. L. Gore & Associates, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3250 W. Kiltie Ln., Flagstaff, AZ, 86005
Sources and methodology
- Original FDA record: P160021/S049
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




